Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma
Authors
Keywords
-
Journal
Journal of Thoracic Oncology
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-12-07
DOI
10.1016/j.jtho.2022.11.027
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Perioperative targeted therapy for oncogene-driven NSCLC
- (2022) Si-Yang Liu et al. LUNG CANCER
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- (2022) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- (2021) Enriqueta Felip et al. LANCET
- Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
- (2021) Karan Seegobin et al. Frontiers in Oncology
- TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
- (2020) G.R. Oxnard et al. ANNALS OF ONCOLOGY
- Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
- (2020) L. Paz-Ares et al. ANNALS OF ONCOLOGY
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer
- (2020) Benjamin C. Creelan et al. BRITISH JOURNAL OF CANCER
- Immunotherapy Treatment Patterns and Outcomes Among ALK+ Patients with Non-small Cell Lung Cancer
- (2020) Mohammad Jahanzeb et al. Clinical Lung Cancer
- Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC
- (2020) Aaron C. Tan et al. Journal of Thoracic Oncology
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib
- (2019) A J Schoenfeld et al. ANNALS OF ONCOLOGY
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
- (2019) Gaurav Singal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Screening for Lung Cancer
- (2018) Peter J. Mazzone et al. CHEST
- A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
- (2018) A. Lisberg et al. Journal of Thoracic Oncology
- Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
- (2018) James Chih-Hsin Yang et al. Journal of Thoracic Oncology
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?
- (2010) T. Le Chevalier ANNALS OF ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started